Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients

Autor: Nicola Cascavilla, Vincenzo Pavone, Giulia Palazzo, Giorgina Specchia, Giovanni Pisapia, Patrizio Mazza, Angelo Michele Carella, Anna Mele, Mario Delia, Francesco Gaudio, Domenico Pastore
Rok vydání: 2018
Předmět:
Adult
Male
medicine.medical_specialty
Immunoconjugates
Transplantation Conditioning
Adolescent
Premedication
Patient characteristics
Graft vs Host Disease
Gastroenterology
03 medical and health sciences
Young Adult
0302 clinical medicine
Antineoplastic Agents
Immunological
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Transplantation
Homologous
Cumulative incidence
Brentuximab vedotin
Bone Marrow Transplantation
Retrospective Studies
Brentuximab Vedotin
Salvage Therapy
Peripheral Blood Stem Cell Transplantation
Hematology
business.industry
Incidence (epidemiology)
Hematopoietic Stem Cell Transplantation
General Medicine
Middle Aged
Hodgkin's lymphoma
medicine.disease
Combined Modality Therapy
Hodgkin Disease
Progression-Free Survival
Transplantation
Treatment Outcome
Drug Resistance
Neoplasm
030220 oncology & carcinogenesis
Female
Stem cell
business
030215 immunology
medicine.drug
Zdroj: Annals of hematology. 98(6)
ISSN: 1432-0584
Popis: This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).
Databáze: OpenAIRE
Externí odkaz: